

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	7	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/CAPLUS Indian patent publication number format defined
NEWS	EXPRESS		NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	LOGIN		Welcome Banner and News Items
NEWS	IPC8		For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:38:11 ON 08 MAY 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:38:22 ON 08 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAY 2007 HIGHEST RN 934385-16-7

DICTIONARY FILE UPDATES: 7 MAY 2007 HIGHEST RN 934385-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524281a.str



chain nodes :

12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

1-14 2-13 3-12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact bonds :

1-14 2-13 3-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 12:38:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 707264 TO ITERATE

100.0% PROCESSED 707264 ITERATIONS

69061 ANSWERS

SEARCH TIME: 00.00.03

L2 69061 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 12:38:55 ON 08 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 May 2007 VOL 146 ISS 20

FILE LAST UPDATED: 7 May 2007 (20070507/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2 full

AB Electroluminescent materials described by the general formula I (Ar1 is an aryl group or an aromatic heterocyclic group; n is an integer of from 0 to 6; L1-6 = independently selected atoms or a group of atoms necessary to form a 6-membered nitrogen-containing aromatic heterocyclic group, provided that ≥ 1 of L1-6 = :N- or -N(R1)-; R1 = H or a substituent, provided that ≥ 1 of Ar1 and R1 = a biaryl group having a bond capable of giving an internal rotational isomerism or a group comprising the biaryl group, provided that adjacent substituent groups existing in the mol. may be condensed with each other to form a ring and Ar1 may be attached directly


to the 6-membered nitrogen-containing ring or may be indirectly attached via one or more substituents on the 6-membered ring) are described in which the electroluminescent material is a mixture comprising ≥ 2 diastereomers represented by I in which ≥ 2 of Ar1 and R1 are biaryl groups having a bond capable of giving an internal rotational isomerism or a group comprising the biaryl group. Electroluminescent devices comprising the electroluminescent materials, optionally with an inorg. fluorescent substance or rare earth metal complex capable of emitting light having a wavelength of a maximum emission different from that of light emitted from the electroluminescent material upon absorption of the light emitted from the electroluminescent material, are also described.

IT 920969-09-1

RL: TEM (Technical or engineered material use); USES (Uses)
(electroluminescent materials based on rotational diastereomer mixts.
and electroluminescent elements using them)

RN 920969-09-1 CAPLUS

CN [5,5'-Biquinolin]-8-amine, N,N-bis([5,5'-biquinolin]-8-yl)- (CA INDEX NAME)



L4 ANSWER 2 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1196663 CAPLUS

DOCUMENT NUMBER: 145:457331

TITLE: Lubricant for metal cladding

INVENTOR(S): Craciun, Alexandru; Duca, Gheorghe; Craciun, Svetlana; Moraru, Victor

PATENT ASSIGNEE(S): Universitatea de Stat din Moldova, Moldova

SOURCE: Mold., 7pp.
CODEN: MDXXCZ

DOCUMENT TYPE: Patent

LANGUAGE: Moldavian


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
MD 1790	F1	20011130	MD 2000-212	20001219 <--
PRIORITY APPLN. INFO.:			MD 2000-212	20001219

AB The invention relates to lubricants and may be used for greasing of different filled friction assemblies. The lubricant for metal cladding containing 8-oxyquinoline and soap grease, supplementary contains the caprolactam and copper hydroxide reaction product. The result of the invention consists in increasing anti-wear- and anti-seizing properties of the proposed lubricant.

IT 148-24-3, 8-Oxyquinoline, uses
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
 (Physical process); TEM (Technical or engineered material use); PROC
 (Process); USES (Uses)
 (lubricant containing; lubricant for metal cladding)
 RN 148-24-3 CAPLUS
 CN 8-Quinolinol (CA INDEX NAME)




L4 ANSWER 3 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:994933 CAPLUS
 DOCUMENT NUMBER: 145:377335
 TITLE: Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C
 INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
 SOURCE: U.S., 358pp., Cont.-in-part of Ser. No. 939,374.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7112600	B1	20060926	US 2002-180558	20020626
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001247550	A	20010911	JP 2000-391904	20001225 <--
US 2003050320	A1	20030313	US 2001-939374	20010824
US 6770666	B2	20040803		
ZA 2003001393	A	20040715	ZA 2003-1393	20020626
US 2007032497	A1	20070208	US 2005-93208	20050328
PRIORITY APPLN. INFO.:			JP 1999-369008	A 19991227
			WO 2000-JP9181	A2 20001222
			JP 2000-391904	A 20001225
			JP 2001-193786	A 20010626
			US 2001-939374	A2 20010824
			JP 2001-351537	A 20011116
			US 2002-180558	A3 20020626
OTHER SOURCE(S):		MARPAT 145:377335		
GI				


AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepared and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of II.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.

IT 347171-19-1P 347171-20-4P 347171-21-5P
 347171-94-2P 347171-95-3P 347171-96-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)


RN 347171-19-1 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(5-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347171-20-4 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(6-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 347171-21-5 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(8-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 347171-94-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[3-[(5-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 347171-95-3 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[3-[(6-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347171-96-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[3-[(8-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:949718 CAPLUS
 DOCUMENT NUMBER: 145:317691
 TITLE: Combustion improvers and stabilizers for biodiesel fuel and biodiesel fuel blends
 INVENTOR(S): Jordan, Frederick L.
 PATENT ASSIGNEE(S): Oryxe Energy International, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 17pp., Cont.-in-part of U.S. Ser. No. 322,048.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006201056	A1	20060914	US 2006-341294	20060127
WO 2001079398	A1	20011025	WO 2001-US40509	20010412 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002194778	A1	20021226	US 2002-84838	20020226
US 6638324	B2	20031028		
US 2003097782	A1	20030529	US 2002-84603	20020226
US 2003167679	A1	20030911	US 2002-171507	20020612
US 7029506	B2	20060418		
PRIORITY APPLN. INFO.:				
			US 2000-197788P	P 20000414
			WO 2001-US40509	A1 20010412
			US 2002-84603	A2 20020226
			US 2002-84838	A2 20020226
			US 2002-171507	A2 20020612
			US 2005-322048	A2 20051229
			US 2001-278011P	P 20010322
AB A fuel additive, typically a combustion improver, for biodiesel fuel and biodiesel fuel-containing diesel fuel blends, contain an ignition accelerator and a second component selected from a plant extract or a synthetic plant extract The ignition accelerator is preferably a peroxide (e.g., di-tert-Bu peroxide). Addnl. components include meadowfoam oil, jojoba oil, and a				

stabilizer or antioxidant. The composition may also enhance the lubricity of the fuel containing biodiesel.

IT 36511-28-1, Ethoxyquinoline
RL: MOA (Modifier or additive use); TEM (Technical or engineered material use); USES (Uses)
(biodiesel fuel stabilizers; combustion improvers and stabilizers for biodiesel fuel and biodiesel fuel blends)
RN 36511-28-1 CAPLUS
CN Quinoline, ethoxy- (9CI) (CA INDEX NAME)



D1-C-Et

L4 ANSWER 5 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:768608 CAPLUS
DOCUMENT NUMBER: 145:180966
TITLE: Compositions and methods using combinations of antiviral agents, broad-spectrum antibiotics, and antiprotozoal agents for the treatment of arthritis
INVENTOR(S): Bonner, Ernest L.; Hines, Robert
PATENT ASSIGNEE(S): Ficaar, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 26pp., Cont.-in-part of U.S. Ser. No. 96,260.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006172956	A1	20060803	US 2005-296575	20051207
US 6087382	A	20000711	US 1999-270962	19990317 <--
US 6465473	B1	20021015	US 2000-510704	20000222
US 2003055022	A1	20030320	US 2002-271117	20021015
US 6765000	B2	20040720		
CA 2502397	A1	20040429	CA 2003-2502397	20031014
WO 2004034987	A2	20040429	WO 2003-US32653	20031014
WO 2004034987	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003284231	A1	20040504	AU 2003-284231	20031014
EP 1558266	A2	20050803	EP 2003-776410	20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503095	T	20060126	JP 2004-545314	20031014
CN 1729006	A	20060201	CN 2003-80103653	20031014
US 2005059640	A1	20050317	US 2004-896612	20040720


US 7053073 B2 20060530
 US 2005137181 A1 20050623 US 2005-54921 20050209
 US 2005272673 A1 20051208 US 2005-96260 20050329
 PRIORITY APPLN. INFO.: US 1999-270962 A2 19990317
 US 2000-510704 A2 20000222
 US 2002-271117 A2 20021015
 US 2004-896612 A2 20040720
 US 2005-54921 A2 20050209
 US 2005-96260 A2 20050329
 WO 2003-US32653 W 20031014

AB The invention provides compns., combinations of antiviral agents, broad-spectrum antibiotics, and antiprotozoal agents, and methods for the treatment of certain conditions such as arthritis, and in particular, reactive arthritis, osteoarthritis, and bursitis, among others.

IT 83-73-8, Iodoquinol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combinations of antiviral agents, broad-spectrum antibiotics, and antiprotozoal agents for treatment of arthritis and bursitis)

RN 83-73-8 CAPLUS

CN 8-Quinololinol, 5,7-diiodo- (CA INDEX NAME)



L4 ANSWER 6 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:671539 CAPLUS
 DOCUMENT NUMBER: 145:98006
 TITLE: Synergistic herbicidal compositions comprising 4-iodo-2-[3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)ureidosulfonyl]benzoic acid esters
 INVENTOR(S): Hacker, Erwin; Hess, Martin; Kehne, Heinz
 PATENT ASSIGNEE(S): Hoechst Schering Agrevo GmbH, Germany
 SOURCE: U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 659,721.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7074743	B1	20060711	US 1999-361461	19990727
DE 19520839	A1	19961212	DE 1995-19520839	19950608 <--
US 5990047	A	19991123	US 1996-659721	19960606 <--
PRIORITY APPLN. INFO.:			DE 1995-19520839	A 19950608
			US 1996-659721	A2 19960606

OTHER SOURCE(S): MARPAT 145:98006

AB Synergistic herbicidal compns. comprise a 4-iodo-2-[3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)ureidosulfonyl]benzoic acid alkyl ester and at least one second component herbicide, such as imazamethabenz, mecoprop, ioxynil and bentazone.

IT 896125-00-1
 RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
 (synergistic herbicidal composition)


RN 896125-00-1 CAPLUS

CN Propanoic acid, 2-[4-[(5-chloro-3-fluoro-2-pyridinyl)oxy]phenoxy]-, 2-propynyl ester, (2R)-, mixt. with [(5-chloro-8-quinolinyl)oxy]acetic acid and methyl 4-iodo-2-[[[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]benzoate monosodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 144550-36-7

CMF C14 H14 I N5 O6 S . Na




● Na

CM 2

CRN 105512-06-9

CMF C17 H13 Cl F N O4


Absolute stereochemistry.



CM 3

CRN 88349-88-6

CMF C11 H8 Cl N O3




REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 7 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:374223 CAPLUS
 DOCUMENT NUMBER: 144:412501
 TITLE: Preparation of 3(5)-acylaminopyrazole derivatives for use as therapeutic agents, particularly antitumor agents
 INVENTOR(S): Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella; Varasi, Mario; Fritzen, Edward L.; Warpehoski, Martha A.; Pierce, Betsy S.; Brasca, Maria Grabriella
 PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy; Pharmacia & Upjohn Company LLC
 SOURCE: U.S., 41 pp., Cont.-in-part of U.S. Ser. No. 372,831, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7034049	B1	20060425	US 2002-48486	20020501
WO 2001012189	A1	20010222	WO 2000-US6699	20000505 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6218418	B1	20010417	US 2000-667603	20000922 <--
PRIORITY APPLN. INFO.:			US 1999-372831	B2 19990812
			WO 2000-US6699	W 20000505
			US 2000-560400	A1 20000428
OTHER SOURCE(S):		MARPAT 144:412501		
GI				



AB Compds. (e.g., N-(5-cyclopropyl-1H-pyrazol-3-yl)-2,2-diphenylacetamide) which are 3-amino-pyrazole derivs. represented by formula I (wherein R = C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 = a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted) are claimed. A process for preparing the 3-aminopyrazole derivs. comprises: (a) reacting RCO₂R₂ (R₂ = alkyl), with MeCN in the presence of a basic agent, to obtain RC(O)CH₂CN; (b) reacting RC(O)CH₂CN with hydrazine hydrate to obtain an 3-amino-5-R-1H-pyrazole; (c) oxidizing the 3-amino-5-R-1H-pyrazole to obtain the nitro analog; (d) reacting the nitro compound with tert-butoxycarbonyl anhydride (Boc₂O) to obtain the N-Boc derivative which was reduced; (e) reacting this amino compound

with R1C(O)X (X = OH or a suitable leaving group) to obtain the N1-Boc-protected I; and (g) hydrolyzing this intermediate in an acidic medium to obtain I. The compds. are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases (no data is given). Pharmaceutical compns. containing I are also claimed.


IT 326826-81-7P, N-(5-Cyclopropyl-1H-pyrazol-3-yl)-2-[4-(8-quinolinyl)phenyl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3(5)-acylaminopyrazole derivs. for use as therapeutic agents, particularly antitumor agents)

RN 326826-81-7 CAPLUS

CN Benzeneacetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-4-(8-quinolinyl)-(9CI) (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:185305 CAPLUS
 DOCUMENT NUMBER: 144:239838
 TITLE: Protein kinase PYK2 (RAFTK) mediated signal transduction and use for screening agents for treating inflammatory bowel diseases and connective tissue diseases
 INVENTOR(S): Schlessinger, Joseph; Okigaki, Mitsuhiro; Gishizky, Mikhail
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: Eur. Pat. Appl., 31 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1630559	A2	20060301	EP 2005-8803	19981231

EP 1630559 A3 20060607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY
EP 1141722 A1 20011010 EP 1998-966125 19981231 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
US 6861442 B1 20050301 US 1999-476484 19991230
US 2004259158 A1 20041223 US 2004-787138 20040227
PRIORITY APPLN. INFO.:
US 1998-114465P P 19981230
EP 1998-966125 A3 19981231
WO 1998-US27871 W 19981231
US 1999-476484 A3 19991230
AB The present invention relates to protein kinase PYK2 (RAFTK) mediated
cellular signal transduction. The present invention relates, inter alia,
to methods for diagnosis, treatment, and identification of therapeutics
for particular inflammation-related diseases or disorders characterized by
an interaction between a PYK2 polypeptide and a natural binding partner.
The invention further provides methods for screening agents for treating
inflammatory bowel diseases and connective tissue diseases.
IT 91-22-5, Quinoline, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(protein kinase PYK2 (RAFTK) mediated signal transduction and use for
screening agents for treating inflammatory bowel diseases and
connective tissue diseases)
RN 91-22-5 CAPLUS
CN Quinoline (CA INDEX NAME)



L4 ANSWER 9 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:101391 CAPLUS
DOCUMENT NUMBER: 144:164293
TITLE: 1,4-Benzodiazepin-2-one derivatives for treatment of
epidermal hyperplasia
INVENTOR(S): Glick, Gary D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 110 pp., Cont.-in-part of U.S.
Ser. No. 795,535.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006025388	A1	20060202	US 2004-886450	20040707
WO 2000066106	A2	20001109	WO 2000-US11599	20000427 <--
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1398033	A2	20040317	EP 2003-27484	20000427
EP 1398033	A3	20040630		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY

US 7125866	B1	20061024	US 2000-700101	20001108
US 2001016583	A1	20010823	US 2001-767283	20010122 <--
US 2003119029	A1	20030626	US 2002-217878	20020813
US 2005261176	A1	20051124	US 2003-427211	20030501
US 7186712	B2	20070306		
US 2004176358	A1	20040909	US 2003-634114	20030804
US 2004241781	A1	20041202	US 2004-795535	20040308
US 2005113460	A1	20050526	US 2004-935333	20040907
CA 2572962	A1	20060209	CA 2005-2572962	20050707
WO 2006014526	A2	20060209	WO 2005-US24060	20050707
WO 2006014526	A3	20070301		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1778204	A2	20070502	EP 2005-769345	20050707
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
AU 2006201605	A1	20060511	AU 2006-201605	20060419

PRIORITY APPLN. INFO.:

US 1999-131761P	P	19990430
US 1999-165511P	P	19991115
US 2000-191855P	P	20000324
WO 2000-US11599	W	20000427
US 2000-700101	A1	20001108
US 2001-767283	A1	20010122
US 2001-312560P	P	20010815
US 2001-313689P	P	20010820
US 2002-396670P	P	20020718
US 2002-217878	A2	20020813
US 2003-427211	A2	20030501
US 2003-634114	A2	20030804
US 2004-795535	A2	20040308
US 1995-443540	B3	19950518
US 1997-881037	A2	19970623
US 1997-943983	B2	19971003
US 1998-18026	B2	19980202
US 1999-165855P	P	19991116
EP 2000-928586	A3	20000427
AU 2002-332560	A3	20020815
US 2004-886450	A2	20040707
WO 2005-US24060	W	20050707


OTHER SOURCE(S): MARPAT 144:164293

AB Derivs. of 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one and compns.
containing said derivs. may be used to treat epidermal hyperplasia, e.g.,
psoriasis. Thus, one compound, Bz-423, reduced epidermal thickness of
retinoic acid-treated human skin in organ culture. The antiproliferative
action of Bz-423 in keratinocytes is associated with reduced Erkl/2
activation but the effect is mediated downstream of the EGF receptor.
Gene expression profiles of Ramos cells treated with Bz-423 and another,
related compound were determined. Structure activity studies of cytotoxic
benzodiazepinones were conducted.

IT 874375-06-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cytotoxicity of; 1,4-Benzodiazepin-2-one derivs. for treatment of

epidermal hyperplasia)
 RN 874375-06-1 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-(4-hydroxy-3-methylphenyl)-1-methyl-3-(6-quinolinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:65871 CAPLUS
 DOCUMENT NUMBER: 144:171023
 TITLE: Preparation of aminothiazoles, aminotriazines, and aminobenzothiepinothiazoles as selective neuropeptide Y (NPY5) antagonists.
 INVENTOR(S): Marzabadi, Mohammad R.; Wong, Wai C.; Noble, Stewart A.; Desai, Manesh N.
 PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
 SOURCE: U.S., 85 pp., Cont.-in-part of 6,218,408.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6989379	B1	20060124	US 2002-9849	20020411
US 6340683	B1	20020122	US 1999-296332	19990422
US 6124331	A	20000926	US 1999-343994	19990630 <--
US 6218408	B1	20010417	US 1999-343762	19990630 <--
WO 2000064880	A1	20001102	WO 2000-US10784	20000421 <--


W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002103201	A1	20020801	US 2002-37859	20020103
US 6569856	B2	20030527		
US 2004019050	A1	20040129	US 2003-420238	20030422
US 2005176709	A1	20050811	US 2005-99960	20050406
US 7189720	B2	20070313		


PRIORITY APPLN. INFO.:
 US 1999-296332 A2 19990422
 US 1999-343762 A2 19990630
 US 1999-343994 A2 19990630
 WO 2000-US10784 W 20000421
 US 2002-37859 A1 20020103
 US 2002-9849 A1 20020411

OTHER SOURCE(S): MARPAT 144:171023

GI




I




- AB Title compds. e.g. I; R1 = H, F, Cl, Br, cyano, OH, NO2, perfluoroalkyl, amino, aminoalkyl, alkyl, etc.; R8 = Q1, NR9CH2(CR14R15)NR10R11, etc.; R5, R9, R10 = H, alkyl; R11 = SO2R16; R14 = H, alkyl, F, (CH2)nOR5; R15 = H, alkyl, F; n = 0-3; p = 0-2; s = 1-6; with provisos, were prepared Thus, N-[6-(4,5-dihydrobenzo[2,3]thiepino[4,5-d][1,3]thiazol-2-ylamino)hexyl]methanesulfonamide (preparation outlined) bound to NPY5 receptors with $K_i = 7.4$ nM.
- IT 874341-27-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of aminothiazoles, aminotriazines, and aminobenzothiepinothiazoles as selective neuropeptide Y antagonists)
- RN 874341-27-2 CAPLUS
- CN 8-Quinolinesulfonamide, N-[[cis-4-[(4,5-dihydro[1]benzothiepin[5,4-d]thiazol-2-yl)amino]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




- IT 296270-53-6P, N-[[4-[4,5-Dihydrobenzo[2,3]thiepino[4,5-d][1,3]thiazol-2-ylamino]cyclohexyl)methyl]-8-quinolinesulfonamide
304006-09-5P, N-[[4-[[[4,6-Di(ethylamino)-1,3,5-triazin-2-yl]amino]methyl]cyclohexyl)methyl]-8-quinolinesulfonamide
304006-54-0P, trans-N-[[4-[[4-(3-Phenyl-5-isoxazolyl)-1,3-thiazol-2-yl]amino]cyclohexyl)methyl]-8-quinolinesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminothiazoles, aminotriazines, and aminobenzothiepinothiazoles as selective neuropeptide Y antagonists)
- RN 296270-53-6 CAPLUS
- CN 8-Quinolinesulfonamide, N-[[4-[(4,5-dihydro[1]benzothiepin[5,4-d]thiazol-2-yl)amino]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)




RN 304006-09-5 CAPLUS

CN 8-Quinolinesulfonamide, N-[[4-[[[4,6-bis(ethylamino)-1,3,5-triazin-2-yl]amino]methyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 304006-54-0 CAPLUS

CN 8-Quinolinesulfonamide, N-[[[trans-4-[[4-(3-phenyl-5-isoxazolyl)-2-thiazolyl]amino]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1262126 CAPLUS
 DOCUMENT NUMBER: 144:22921
 TITLE: Preparation of thiobenzimidazole derivatives as chymase inhibitors
 INVENTOR(S): Tsuchiya, Naoki; Mizuno, Tsuyoshi; Saitou, Hiroshi; Matsumoto, Yoshiyuki; Takeuchi, Susumu; Hase, Naoki
 PATENT ASSIGNEE(S): Teijin Limited, Japan
 SOURCE: U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 963,710.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005267148	A1	20051201	US 2005-129508	20050516
WO 2000003997	A1	20000127	WO 1999-JP3799	19990714 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001053291	A1	20010726	WO 2001-JP271	20010117 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CN 1680339	A	20051012	CN 2005-10052604	20010117
US 2004010004	A1	20040115	US 2002-169866	20020710
US 2004162311	A1	20040819	US 2004-777067	20040213
US 7176320	B2	20070213		
US 2006040976	A1	20060223	US 2004-963710	20041014
PRIORITY APPLN. INFO.:				
			JP 1998-200250	A 19980715
			WO 1999-JP3799	W 19990714
			JP 2000-7533	A 20000117
			JP 2000-392303	A 20001225
			US 2001-743483	B1 20010110

WO 2001-JP271	W 20010117
US 2002-169866	B1 20020710
US 2004-777067	A2 20040213
US 2004-963710	A2 20041014
CN 2001-806662	A3 20010117

OTHER SOURCE(S): MARPAT 144:22921
GI



AB The title compds. (I) [R1, R2 = H, F, Cl, Br, iodo, CF3, cyano, HO, Me, Et, n- or i-Pr, n-, i-, s- or t-Bu, MeO, EtO, n- or i-propyloxy, n-, i-, s- or t-butyloxy; or R1 and R2 together represent (un)substituted OCH2O, OCH2CH2O or CH2CH2CH2 ; A = (un)substituted CH2, CH2CH2, n- or i-propylene, n-, i- or t-butylene, phenylene, indenylene, naphthylene, pyridylene, furanylene, thiophenylene, pyrimidylene, benzophenylene, benzimidazolene, quinolylene, indolene, or benzoathiazolene; E = CO2R3, SO3R3, CONHR3, SO2NHR3, tetrazolyl, 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl (wherein R3 = H, Me, Et, n- or i-Pr, n-, i-, s- or t-Bu); G = (un)substituted CH2, CH2CH2, n- or i-propylene, n-, i- or t-butylene; m = an integer of 0-2; when m is 0 and A = (un)substituted CH2, CH2CH2, n- or i-propylene, or n-, i- or t-butylene, then J = (un)substituted n- or i-Pr, n-, i-, s- or t-Bu, n-, i-, ne- or t-pentyl, cyclohexyl, indenyl, furanyl, thiophenyl, pyrimidyl, benzofuranyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalyl, benzoxadiazolyl, benzothiadiazolyl, indolyl, N-methylindolyl, benzothiazolyl, benzothiophenyl, benzisoxazolyl, or naphthyl; other combinations of m, A, and J are also defined; X = CH or N] are prepared. These compds. have a potent activity of inhibiting human chymase and are potential preventive and/or therapeutic agents clin. applicable to various diseases in which human chymase is involved, including inflammatory diseases, allergic diseases, diseases of respiratory organs, diseases of circulatory organs, or diseases of bone/cartilage metabolism. Thus, 50 mg 1-[(1-methylindol-3-yl)methyl]benzimidazole-2-thiol and 59 mg 2-bromomethylbenzoic acid Me ester were added to a mixture of 12 mg NaH and 2 mL THF and then the mixture was stirred at 60° for 1 h, and treated with H2O to give, after workup and silica gel chromatog., 54 mg 2-[[[1-[(1-methylindol-3-yl)methyl]benzimidazol-2-yl]thio]methyl]benzoic acid Me ester (yield 74%) which was dissolved in 2 mL THF and 1 mL MeOH, treated with 0.5 mL 4 N LiOH, stirred at room temperature overnight, quenched by adding 6 N HCl to give,


after workup, 2-[[[1-[(1-methylindol-3-yl)methyl]benzimidazol-2-yl]thio]methyl]benzoic acid. Compds. of this invention in vitro showed IC50 values of 1 nM to 100 nM against human mast cell chymase. A formulation is given.

IT 255397-02-5P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiobenzimidazole derivs. as chymase inhibitors and preventive and/or therapeutic agents for various diseases involving human chymase)

RN 255397-02-5 CAPLUS

CN Benzoic acid, 2-[[[5,6-dimethyl-1-(8-quinolinylmethyl)-1H-benzimidazol-2-yl]thio]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:547257 CAPLUS
 DOCUMENT NUMBER: 143:77866
 TITLE: Preparation of nitrate esters having a β - or γ -sulfur atom for protection of cells/tissues from oxidative damage.
 INVENTOR(S): Thatcher, Gregory R. j.; Bennett, Brian M.; Reynolds, James N.; Boegman, Roland J.; Jhamandas, Khem
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 83 pp., Cont.-in-part of U.S. Ser. No. 147,808.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005137191	A1	20050623	US 2004-943264	20040917
US 5807847	A	19980915	US 1996-658145	19960604 <--
US 5883122	A	19990316	US 1997-867856	19970603 <--
US 6310052	B1	20011030	US 1999-267379	19990315 <--
US 7115661	B1	20061003	US 1999-473713	19991229
EP 1518553	A2	20050330	EP 2004-28372	20001227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2002177622	A1	20021128	US 2002-147808	20020520
US 6916835	B2	20050712		
WO 2006029532	A1	20060323	WO 2005-CA1417	20050916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:
 US 1996-658145 A2 19960604
 US 1997-867856 A2 19970603
 US 1999-267379 A3 19990315
 US 1999-473713 A2 19991229
 US 2002-147808 A2 20020520
 EP 2000-986925 A3 20001227
 US 2001-851591 A3 20010510

US 2002-108513 A3 20020329
US 2004-943264 A 20040917

OTHER SOURCE(S): MARPAT 143:77866

AB YXCR3R4(CR17R18)n(CR1R2)mONO2 [m, n = 0-10; R3, R4, R17 = H, nitrate, A; R1 = H, A; A = (substituted) (unsatd.) (cyclic) aliphatyl; R1R3, R4R17 = aliphatyl linkage; R2, R18 = H, A, XY; X = F, Cl, Br, Cl, NO2, CH2, CF2, O, NH, NMe, cyano, NHOH, N3, S, SCN, SO, SO2, etc.; Y = null, F, Cl, Br, Cl, Me, CF2H, CF3, OH, NH2, S, SCN, SH, etc.; with provisos], were prepared Thus, [O2NOCH2CH(ONO2)CH2S]2 (prepared via the corresponding Bunte salt) at 200 µmol/kg s.c. gave virtually complete protection against 6-OHDA killing of dopaminergic neurons in rats.


IT 349481-58-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of nitrate esters having β- or γ-sulfur atom for protection of cells/tissues from oxidative damage)

RN 349481-58-9 CAPLUS

CN 1,2-Propanediol, 3-(8-quinolinyldithio)-, dinitrate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:345093 CAPLUS

DOCUMENT NUMBER: 142:357043

TITLE: Process for nitration of aromatic compounds with dinitrogen pentoxide in liquid sulfur dioxide and organic solvents

INVENTOR(S): Bakke, Jan; Ranes, Eli; Arnestad, Berit; Hegbom, Ingrid

PATENT ASSIGNEE(S): Norsk Hydro AS, Norway

SOURCE: Norw., 13 pp.

CODEN: NOXXAJ

DOCUMENT TYPE: Patent

LANGUAGE: Norwegian


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
NO 300013	B1	19970317	NO 1995-367	19950201 <--
NO 9500367	A	19960802		
PRIORITY APPLN. INFO.:			NO 1995-367	19950201

OTHER SOURCE(S): CASREACT 142:357043; MARPAT 142:357043


GI



AB The invention relates to a novel nitration system, consisting of dinitrogen pentoxide dissolved in a mixture of liquid sulfur dioxide and an organic solvent. The invention also relates to a procedure for the nitration of aromatic compds., especially pyridines and substituted pyridines, where the nitration system used is dinitrogen pentoxide dissolved in a mixture of liquid sulfur dioxide and an organic solvent. A nitration system for nitration of aromatic compds., characterized by that the organic solvent is an ether, substituted hydrocarbons, or amides and the amount of sulfur dioxide used is between 1 mol SO₂ per mol of aromatic compound to 50 vol% SO₂/total volume of solvent and the reaction time is between 10 min and 2 h. A nitration system as described above, characterized by that the amount of sulfur dioxide used is more than 1.5 mol SO₂ per mol of aromatic compound. A procedure for the nitration of aromatic compds. I (X = R₅C:CR₆, S, N:CR₇; R₁-R₇ = independently H, C1-4 alkyl, C1-4 alkoxy, C1-4 alkyloxycarbonyl; R₁ and R₂ or R₂ and R₃, together with the carbon atoms they are connected to, form a 6-membered aromatic ring) characterized by that the aromatic compound is nitrated by a nitration system consisting of dinitrogen pentoxide dissolved in a mixture of liquid sulfur dioxide and an organic solvent, and that the nitration reaction is carried out at a temperature of -100 °C to +20 °C. A procedure as described above, characterized by that the nitration reaction is carried out at -20 °C to +20 °C. A procedure as described above, characterized by that the organic solvent is THF.


IT 6623-91-2P, 6-Methoxy-5-nitroquinoline
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (process for nitration of aromatic compds. with dinitrogen pentoxide in liquid sulfur dioxide and organic solvents)

RN 6623-91-2 CAPLUS
 CN Quinoline, 6-methoxy-5-nitro- (9CI) (CA INDEX NAME)




IT 91-22-5, Quinoline, reactions 5263-87-6, 6-Methoxyquinoline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (process for nitration of aromatic compds. with dinitrogen pentoxide in liquid sulfur dioxide and organic solvents)

RN 91-22-5 CAPLUS
 CN Quinoline (CA INDEX NAME)




RN 5263-87-6 CAPLUS
 CN Quinoline, 6-methoxy- (CA INDEX NAME)



L4 ANSWER 14 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:313150 CAPLUS
 DOCUMENT NUMBER: 142:373566
 TITLE: Preparation of 2- or 4-(phenylthio)cinnamides as cell
 adhesion-inhibiting antiinflammatory and
 immune-suppressive compounds
 INVENTOR(S): Link, James; Liu, Gang; Pei, Zhonghua; Von Geldern,
 Tom; Winn, Martin; Xin, Zhili; Boyd, Steven A.; Zhu,
 Gui-Dong; Freeman, Jennifer C.; Gunawardana, Indrani
 W.; Staeger, Michael A.; Jae, Hwan-Soo; Lynch, John
 K.; Wang, Sheldon
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: U.S., 123 pp., Cont.-in-part of U.S. Ser. No. 474,517.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6878700	B1	20050412	US 2000-541795	20000331
CA 2369238	A1	20001012	CA 2000-2369238	20000403 <--
WO 2000059880	A1	20001012	WO 2000-US8895	20000403 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 200041944	A	20001023	AU 2000-41944	20000403 <--
AU 774564	B2	20040701		
BR 2000009426	A	20020409	BR 2000-9426	20000403
EE 200100513	A	20021216	EE 2001-513	20000403
JP 2004513063	T	20040430	JP 2000-609392	20000403
AT 275543	T	20040915	AT 2000-921654	20000403
NZ 515237	A	20041126	NZ 2000-515237	20000403
EP 1481968	A2	20041201	EP 2004-20808	20000403
EP 1481968	A3	20050119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
CZ 296856	B6	20060712	CZ 2001-3522	20000403
BG 106029	A	20020531	BG 2001-106029	20011018
HR 2001000776	A1	20021231	HR 2001-776	20011023
HR 2001000776	B1	20060228		
HK 1040985	A1	20050218	HK 2002-102655	20020409
US 2004116518	A1	20040617	US 2003-725212	20031201
US 6867203	B2	20050315		
US 2005250768	A1	20051110	US 2004-921965	20040820
AU 2004205260	A1	20040923	AU 2004-205260	20040825
PRIORITY APPLN. INFO.:				
			US 1998-114097P	P 19981229
			US 1999-474517	A2 19991229
			US 1999-286645	A 19990402
			US 2000-541795	A 20000331
			EP 2000-921654	A3 20000403
			WO 2000-US8895	W 20000403
			US 2000-695040	A1 20001024
OTHER SOURCE(S): MARPAT 142:373566				
GI				



AB The title compds. (I) [wherein R1, R2, R4, R5 = independently H, halo, (halo)alkyl, alkoxy, cyano, NO₂, CHO, heterocyclylsulfanyl, (un)substituted cis- or trans-cinnamide; R3 = (un)substituted cis- or trans-cinnamide; Ar = (un)substituted (hetero)aryl] were prepared as cell adhesion inhibitors for the treatment of inflammatory and immune diseases. Examples include syntheses for 443 invention compds. and data for 3 bioassays. For instance, a mixture of 2-[(2,4-dichlorophenyl)thio]benzaldehyde (preparation given), malonic acid, piperidine in anhydrous pyridine was heated

at 110°C for 2 h and then treated with aqueous HCl to give trans-2-[(2,4-dichlorophenyl)thio]cinnamic acid (91%). Conversion to the acid chloride followed by amidation with 6-amino-1-hexanol gave (E)-II (90%). In an integrin LFA-1/ICAM-1 biochem. interaction assay, I demonstrated inhibition at 4 μM. In cell-based adhesion assays which measure the ability of test compds. to block adherence of JY-8 cells (a human EBV-transformed B cell line expressing LFA-1 on its surface) to immobilized ICAM-1 or ICAM-3, I exhibited blocking activity at 4 μM and 0.6 μM, resp.

IT 280750-88-1P 280752-37-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (phenylthio)cinnamides as cell adhesion inhibitors by coupling of thiophenols with halobenzaldehydes, conversion to cinnamic acids, amidation, and optional derivatization)

RN 280750-88-1 CAPLUS

CN Piperazine, 1-acetyl-4-[(2E)-3-[3-chloro-4-[(5-chloro-8-ethoxy-7-quinolinyl)thio]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 280752-37-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2E)-3-[5-[(2-methoxyphenyl)thio]-8-quinolinyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



IT 130-16-5, 5-Chloro-8-hydroxyquinoline 91676-22-1,
 5-Chloro-8-ethoxy-7-iodoquinoline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (phenylthio)cinnamides as cell adhesion inhibitors by
 coupling of thiophenols with halobenzaldehydes, conversion to cinnamic
 acids, amidation, and optional derivatization)
 RN 130-16-5 CAPLUS
 CN 8-Quinolinel, 5-chloro- (CA INDEX NAME)



RN 91676-22-1 CAPLUS
 CN Quinoline, 5-chloro-8-ethoxy-7-iodo- (9CI) (CA INDEX NAME)




IT 157437-38-2P, 5-Chloro-8-(trifluoromethanesulfonyloxy)quinoline
 280753-21-1P, 5-Chloro-8-[(E)-2-(methoxycarbonyl)ethenyl]quinoline
 280753-23-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of (phenylthio)cinnamides as cell adhesion inhibitors by

coupling of thiophenols with halobenzaldehydes, conversion to cinnamic acids, amidation, and optional derivatization)

RN 157437-38-2 CAPLUS


CN Methanesulfonic acid, 1,1,1-trifluoro-, 5-chloro-8-quinolinyl ester (CA INDEX NAME)



RN 280753-21-1 CAPLUS

CN 2-Propenoic acid, 3-(5-chloro-8-quinolinyl)-, methyl ester, (2E)- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 280753-23-3 CAPLUS

CN 2-Propenoic acid, 3-[5-[(2-methoxyphenyl)thio]-8-quinolinyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 126 THERE ARE 126 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:261893 CAPLUS

DOCUMENT NUMBER: 144:216366

TITLE: The copper, lead and zinc recovery of the minerals partial oxidated with chelating action reagents

AUTHOR(S): Oprea, Gabriela; Mihali, Cristina

CORPORATE SOURCE: Universitatea de Nord Baia Mare, Baia Mare, 4800, Rom.

SOURCE: Studia Universitatis Babes-Bolyai, Chemia (

2001), 46(1-2), 175-181

CODEN: SUBCAB; ISSN: 1224-7154

PUBLISHER: Studia Universitatis Babes-Bolyai

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The flotation of copper minerals with salicylaldoxyne shows selectivity of the reagent. Oxine (8-hydroxyquinoline) is less selective because part of the calcite floates and decreases the copper content of the concentrate In this

case is demonstrated the utility of the flotation in two steps when the recovery percentage of the copper increases in the concentrate and decrease in the raffinate. The flotation of lead and zinc minerals partially oxidized by oxyne shows an increase in the recovery of lead and zinc when the flotation in two stages is replaced by the flotation in three stages, and better than the replacing of one stage with two stages of flotation. For copper, lead and zinc partially oxidized minerals, the results obtained using oxyne are superior to those obtained by preliminary sulfating the surface. By using of oxyne the recovery and metal content both increase.


IT 148-24-3, Oxine, processes

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)

(copper, lead and zinc recovery from partially oxidized ore by flotation with chelating agents)

RN 148-24-3 CAPLUS

CN 8-Quinolinol (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:185397 CAPLUS

DOCUMENT NUMBER: 142:266351

TITLE: Antimicrobial perfuming compositions

INVENTOR(S): Bretler, Gil

PATENT ASSIGNEE(S): Switz.

SOURCE: U.S. Pat. Appl. Publ., 6 pp., Cont.-in-part of U.S. Ser. No. 106,649.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


US 2005049301	A1	20050303	US 2004-962075	20041007
WO 2001024769	A1	20010412	WO 2000-IB1389	20000928 <--
W: BR, JP, MX, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2002142364	A1	20021003	US 2002-106649	20020325
PRIORITY APPLN. INFO.:			WO 1999-IB1618	A 19991004
			WO 1999-IB1660	A 19991011
			WO 2000-IB1389	A1 20000928
			US 2002-106649	A2 20020325

AB The present invention describes perfumes and perfuming comps. having an antimicrobial activity and containing effective amts. of certain perfuming ingredients which have an antimicrobial activity as evaluated by the Microbial Reduction Test. A composition contained benzyl acetate, hexylcinnamaldehyde, (2E,6Z)-2,6-nonadien-1-ol, citronellol, coumarin, γ -dodecalactone, Lorysia, heliotropine, isobutylquinoleine, Lilial, Mayol, phenylethanol, phenylhexanol, and Polysantol.

IT 1333-58-0
 RL: COS (Cosmetic use); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
 (antimicrobial perfuming comps.)

RN 1333-58-0 CAPLUS

CN Quinoline, (2-methylpropyl)- (CA INDEX NAME)



D1-Bu-i

L4 ANSWER 17 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:151107 CAPLUS

DOCUMENT NUMBER: 142:283362

TITLE: Corrosion-inhibiting mixture with propargyl alcohol for use in acidified petroleum formations

INVENTOR(S): Schwartz, Kevin; Fauke, Allen R.; Scherubel, Gary A.; Reid, Robert

PATENT ASSIGNEE(S): Clearwater, Inc., USA

SOURCE: Can. Pat. Appl., 16 pp.
 CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2280124	A1	20000217	CA 1999-2280124	19990812 <--
PRIORITY APPLN. INFO.:			US 1998-135271	A 19980817

AB The corrosion-inhibitor mixture for petroleum fluids typically acidified with HCl contains: (a) propargyl alc. (as active inhibitor) at 2-20%; (b) quinaldine at 1-10%; (c) quinolinium compound at 1-10%, especially as Me, methylnaphthalene, or benzyl quinolinium chloride; (d) preferably dodecylbenzene sulfonic acid (I) at 10-30%; and (e) the balance as a blend of solvents with MeOH 15-25, ethylene glycol 10-20, and Butyl Cellosolve 5-10%. The inhibitor mixture is suitable for protecting steel parts against corrosion in petroleum-field applications, and is resistant to formation of sludge and emulsion in service. The typical acidic test solution with

corrosion inhibitor contains HCl 40, MeOH 18, ethylene glycol 13.6, Butyl Cellosolve 6, quinaldine 1, I 15.6, chloromethylnaphthalene quaternary of quinoline 1, and propargyl alc. 4.8%.


IT 15619-48-4, Benzyl quinolinium chloride

RL: MOA (Modifier or additive use); USES (Uses)

(petroleum fluids with; corrosion-inhibiting mixture with propargyl alc. for acidified petroleum fluids)

RN 15619-48-4 CAPLUS

CN Quinolinium, 1-(phenylmethyl)-, chloride (1:1) (CA INDEX NAME)



● Cl⁻

L4 ANSWER 18 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:78507 CAPLUS

DOCUMENT NUMBER: 142:127549

TITLE: A method for producing a combination kit containing chloroquine and 3-[1-((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)ethylidene]dihydro-2(3H)-furanone for the treatment of malaria caused by Plasmodium vivax

INVENTOR(S): Pinto, Francis Joseph; Piramal, Swati Ajay; Pratap, Ram; Bhaduri, Amiya Prasad; Thapliyal, Harsh Pati; Puri, Sunil Kumar; Dutta, Guru Prasad; Dwivedi, Anil Kumar; Singh, Satyawan; Srivastava, Pratima; Pandey, Vikash Chandra; Srivastava, Sudhir; Singh, Shio Kumar; Gupta, Ram Chandra; Srivastava, Jagdishwar Sahai; Asthana, Omkar Prasad

PATENT ASSIGNEE(S): Nicholas Piramal India Ltd., India; Council of Scientific & Industrial Research

SOURCE: Indian, 17 pp.

CODEN: INXXAP

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 186617	A1	20011013	IN 2000-MU489	20000529 <--
PRIORITY APPLN. INFO.:			IN 2000-MU489	20000529


AB The invention discloses a method for producing a combination kit for the treatment of malaria caused by Plasmodium vivax having individual doses of an antimalarial agent, 3-[1-((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)ethylidene]dihydro-2(3H)-furanone (I) in the form of capsules; individual dose of the antimalarial agent, chloroquine in the form of tablets, and instruction material for the administration of the two antimalarial drugs. The combination kit is particularly suited for a 6 day treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent of 300 mg base), three to taken on day one and one each on days two and three; and five capsules containing 25 mg of I, one each to be taken on days two to six.

IT 90-34-6, Primaquine

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(chloroquine-dihydrofuranone derivative combination for treatment of malaria caused by Plasmodium vivax)

RN 90-34-6 CAPLUS

CN 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)- (CA INDEX NAME)




IT 79781-00-3

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chloroquine-dihydrofuranone derivative combination for treatment of malaria caused by Plasmodium vivax)

RN 79781-00-3 CAPLUS

CN 2(3H)-Furanone, dihydro-3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]- (CA INDEX NAME)



L4 ANSWER 19 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1085725 CAPLUS

DOCUMENT NUMBER: 143:59969

TITLE: Preparation of indazoles having antiasthmatic, antiallergic, antiinflammatory, and immunomodulating action.

INVENTOR(S): Hoefgen, Norbert; Brune, Kay; Schindler, Rudolf; Poppe, Hildegard

PATENT ASSIGNEE(S): Arzneimittelwerk Dresden G.m.b.H., Germany

SOURCE: Can. Pat. Appl., 51 pp.

CODEN: CPXXEB


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2271831	A1	19991111	CA 1999-2271831	19990511 <--
PRIORITY APPLN. INFO.:			DE 1998-19821001	A 19980511
OTHER SOURCE(S):	CASREACT 143:59969; MARPAT 143:59969			
GI				



AB Title compds. [I; X = SO₂, SO, (CH₂)_p, (CH₂)_pO, (CH₂)_pCO, (CH₂)_pCONH, (CH₂)_pCH:CH, etc.; Y = (CH₂)_p, (CH₂)_pO, (CH₂)_pCO, (CH₂)_pCONH, (CH₂)_pCH:CH, etc.; p = 1-4; Z = O, S, SO, SO₂, O(CH₂)_p, NH, NHCO, NHCO₂, NHCH₂CO, etc.; R₁-R₃ = mono-, bi-, tricyclic (unsatd.) carbocyclyl, heterocyclyl; R₁ can further = H; R₃Z can further = NO₂; with provisos], were prepared Thus, 5-methoxy-1H-indazol-3-yl tosylate in Me₂SO was treated with NaH and then with 1-(2-bromo-4,6-difluorophenoxy)-2-chloroethane in Me₂SO followed by stirring at 90° for 3 h to give 45.3% 3-[2-(2-bromo-4,6-difluorophenoxy)ethoxy]-5-methoxy-1-(toluene-4-sulfonyl)-1H-indazole. The latter inhibited peptidyl prolyl isomerase by 95% at 10 μM.


IT 249933-03-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indazoles having antiasthmatic, antiallergic, antiinflammatory, and immunomodulating action)

RN 249933-03-7 CAPLUS


CN 1H-Indazole, 3-[2-(3,4-dichlorophenyl)-2-oxoethoxy]-5-methoxy-1-(8-quinolinylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 37820 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:1047043 CAPLUS
 DOCUMENT NUMBER: 142:300654
 TITLE: Transformer oil

INVENTOR(S): Fefer, Michael
 PATENT ASSIGNEE(S): Petro-Canada, Can.
 SOURCE: Can. Pat. Appl., 15 pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2263046	A1	20000825	CA 1999-2263046	19990225 <--
PRIORITY APPLN. INFO.:			CA 1999-2263046	19990225
AB A transformer oil comprises a base stock and a non-unsatd., unsubstituted compound having at least one hydrogen donor.				
IT 91-22-5, Quinoline, uses				
RL: TEM (Technical or engineered material use); USES (Uses) (transformer oil containing)				
RN 91-22-5 CAPLUS				
CN Quinoline (CA INDEX NAME)				



=> d his

(FILE 'HOME' ENTERED AT 12:38:11 ON 08 MAY 2007)

FILE 'REGISTRY' ENTERED AT 12:38:22 ON 08 MAY 2007

L1 STRUCTURE UPLOADED
 L2 69061 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:38:55 ON 08 MAY 2007

L3 45292 S L2 FULL
 L4 37820 S L3 AND PY<2002

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	108.35	280.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.60	-15.60

STN INTERNATIONAL LOGOFF AT 12:40:23 ON 08 MAY 2007